Successful implantation and treatment underway in world’s first patient receiving experimental therapy for Rheumatoid Arthritis (RA) using splenic nerve stimulation Electrical stimulation of nerves ...

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness. FDA approves progression of Galvani’s splenic ...

GSK and Verily joint venture Galvani Bioelectronics laparoscopically implanted a neurostimulator in a rheumatoid arthritis (RA) patient as part of the NHS Greater Glasgow & Clyde Health Board’s ...

Please provide your email address to receive an email when new articles are posted on . Galvani Bioelectronics has treated its first patient with a novel bioelectronic implant stimulating the splenic ...

A patient has become the first in the US to receive an experimental electronic implant developed by a Verily-backed biotech to treat rheumatoid arthritis, a first in the cutting-edge field of ...

The FINANCIAL — GSK on August 1 announced an agreement with Verily Life Sciences LLC (formerly Google Life Sciences), an Alphabet company, to form Galvani Bioelectronics to enable the research, ...

Galvani Bioelectronics, a joint venture between Verily and GSK, recently announced the first successful implantation of a neurostimulator that uses splenic nerve stimulation as an experimental therapy ...

SAN FRANCISCO--(BUSINESS WIRE)--Galvani Bioelectronics, a clinical-stage company formed through a strategic partnership between GlaxoSmithKline (GSK) and Verily Life Sciences (Verily) in 2016 with the ...

FDA approves progression of Galvani’s splenic neuromodulation therapy to the randomized, controlled stage of clinical feasibility testing in rheumatoid arthritis after review of initial patient safety ...